Nuclear localization of metabolic enzymes in immunity and metastasis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1868, Issue 2, 2017, Pages 359-371

  He, Yuchen ^a,b,c   Gao, Menghui ^a,b,c   Cao, Yiqu ^a,b,c   Tang, Haosheng ^a,b,c   Liu, Shuang ^a   Tao, Yongguang ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

ACLY; Cancer; Immunity; Metabolic enzymes; Metastasis; PDC; PKM2

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE KINASE; CARRIER PROTEIN; MEMBRANE PROTEIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; CYTOPLASM; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME SYNTHESIS; FOOD AVAILABILITY; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HOMEOSTASIS; HUMAN; METASTASIS; MITOCHONDRION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR IMMUNITY; ANIMAL; CELL NUCLEUS; IMMUNITY; METABOLISM; NEOPLASM; NUCLEOCYTOPLASMIC TRANSPORT; PHYSIOLOGY; PROTEIN TRANSPORT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ATP CITRATE (PRO-S)-LYASE; CARRIER PROTEINS; CELL NUCLEUS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN TRANSPORT; PYRUVATE DEHYDROGENASE COMPLEX; THYROID HORMONES;

EID: 85026633269     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2017.07.002     Document Type: Review

References (170)

1. Ja, V.D.K., Verrijzer, C.P., Undercover: gene control by metabolites and metabolic enzymes. Genes Dev., 30, 2016, 2345.
2. He, X., Yan, B., Liu, S., Jia, J., Lai, W., Xin, X., Tang, C.E., Luo, D., Tan, T., Jiang, Y., Shi, Y., Liu, Y., Xiao, D., Chen, L., Liu, S., Mao, C., Yin, G., Cheng, Y., Fan, J., Cao, Y., Muegge, K., Tao, Y., Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res. 76 (2016), 5743–5755.
3. Chen, Y., Sprung, R., Tang, Y., Ball, H., Sangras, B., Kim, S.C., Falck, J.R., Peng, J., Gu, W., Zhao, Y., Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics, 6, 2007, 812.
4. Xiao, D., Huang, J., Pan, Y., Li, H., Fu, C., Mao, C., Cheng, Y., Shi, Y., Chen, L., Jiang, Y., Yang, R., Liu, Y., Zhou, J., Cao, Y., Liu, S., Tao, Y., Chromatin remodeling factor LSH is upregulated by the LRP6-GSK3beta-E2F1 axis linking reversely with survival in gliomas. Theranostics 7 (2017), 132–143.
5. Liu, S., Tao, Y.G., Chromatin remodeling factor LSH affects fumarate hydratase as a cancer driver. Chin. J. Cancer, 35, 2016, 72.
6. Menendez, J.A., Lupu, R., Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer, 7, 2007, 763.
7. Medes, G., Thomas, A., Weinhouse, S., Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res., 13, 1953, 27.
8. Pearce, E.L., Poffenberger, M.C., Chang, C.H., Jones, R.G., Fueling immunity: insights into metabolism and lymphocyte function. Science, 342, 2013, 1242454.
9. Buck, M.D., Sowell, R.T., Kaech, S.M., Pearce, E.L., Metabolic instruction of immunity. Cell, 169, 2017, 570.
10. Man, K., Kutyavin, V.I., Chawla, A., Tissue immunometabolism: development, physiology, and pathobiology. Cell Metab. 25 (2016), 11–26.
11. Mei, X., Qiao, Z., Li, J., Liu, J., Song, S., Zhao, X., Miao, P., Tang, T., Wang, L., Liu, W., miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget, 7, 2016, 44252.
12. Warburg, O., Wind, F., Negelein, E., The metabolism of tumors in the body. J. Gen. Physiol., 8, 1927, 519.
13. Liu, S., Yan, B., Lai, W., Chen, L., Xiao, D., Xi, S., Jiang, Y., Dong, X., An, J., Chen, X., Cao, Y., Tao, Y., As a novel p53 direct target, bidirectional gene HspB2/alphaB-crystallin regulates the ROS level and Warburg effect. Biochim. Biophys. Acta 1839 (2014), 592–603.
14. Kuhajda, F.P., Jenner, K., Wood, F.D., Hennigar, R.A., Jacobs, L.B., Dick, J.D., Pasternack, G.R., Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. U. S. A., 91, 1994, 6379.
15. Jiang, Y., Liu, S., Chen, X., Cao, Y., Tao, Y., Genome-wide distribution of DNA methylation and DNA demethylation and related chromatin regulators in cancer. Biochim. Biophys. Acta 1835 (2013), 155–163.
16. Watson, J.A., Fang, M., Lowenstein, J.M., Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch. Biochem. Biophys., 135, 1969, 209.
17. Chypre, M., Zaidi, N., Smans, K., ATP-citrate lyase: a mini-review. Biochem. Biophys. Res. Commun. 422 (2012), 1–4.
18. Wang, Q., Li, S., Jiang, L., Zhou, Y., Li, Z., Shao, M., Li, W., Liu, Y., Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice. J. Lipid Res. 51 (2010), 2516–2526.
19. Chu, K.Y., Lin, Y., Hendel, A., Kulpa, J.E., Brownsey, R.W., Johnson, J.D., ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells. J. Biol. Chem., 285, 2010, 32606.
20. Fukuda, H., Katsurada, A., Iritani, N., Effects of nutrients and hormones on gene expression of ATP citrate-lyase in rat liver. Eur. J. Biochem. 209 (1992), 217–222.
21. Macdonald, M.J., Hasan, N.M., Sabat, G., Fahien, L.A., Feasibility of pathways for transfer of acyl groups from mitochondria to the cytosol to form short chain acyl-CoAs in the pancreatic beta cell. J. Biol. Chem. 282 (2007), 30596–30606.
22. Linn, T.C., Srere, P.A., Binding of ATP citrate lyase to the microsomal fraction of rat liver. J. Biol. Chem. 259 (1984), 13379–13384.
23. KE, W., H.G., UM, S., TV, B., JR, C., CB, T., ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324 (2009), 1076–1080.
24. Zhao, S., Torres, A., Henry, R.A., Trefely, S., Wallace, M., Lee, J.V., Carrer, A., Sengupta, A., Campbell, S.L., Kuo, Y.M., ATP-citrate lyase controls a glucose-to-acetate metabolic switch. Cell Rep., 17, 2016, 1037.
25. Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Soga, T., Taguchi, R., Seimiya, H., Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. Int. J. Cancer, 135, 2014, 37.
26. Mashima, T., Seimiya, H., Tsuruo, De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 100 (2009), 1369–1372.
27. Lemus, H.N., Mendivil, C.O., ATP-citrate lyase: emerging target in the treatment of dyslipidemia. J. Clin. Lipidol. 9 (2015), 384–389.
28. Burke, A.C., Huff, M.W., ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr. Opin. Lipidol., 28, 2017, 193.
29. Zaidi, N., Swinnen, J.V., Smans, K., ATP-citrate lyase: a key player in cancer metabolism. Cancer Res., 72, 2012, 3709.
30. Choudhary, C., Weinert, B.T., Nishida, Y., Verdin, E., Mann, M., The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 15 (2014), 536–550.
31. H.J., V.D.P., G.K., N-terminal acetylation and other functions of Nα-acetyltransferases. Biol. Chem. 393 (2012), 291–298.
32. Macdonald, M.J., Longacre, M.J., Langberg, E.C., Tibell, A., Kendrick, M.A., Fukao, T., Ostenson, C.G., Decreased levels of metabolic enzymes in pancreatic islets of patients with type 2 diabetes. Diabetologia 52 (2009), 1087–1091.
33. Pearce, N., Yates, J., Berkhout, T., Jackson, B., Tew, D., Boyd, H., Camilleri, P., Sweeney, P., Gribble, A., Shaw, A., The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J., 334(Pt 1), 1998, 113.
34. Swinnen, J.V., Brusselmans, K., Verhoeven, G., Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006), 358–365.
35. Icard, P., Poulain, L., Lincet, H., Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta, 1825, 2012, 111.
36. Zong, H., Zhang, Y., You, Y., Cai, T., Wang, Y., Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer. Med. Oncol., 32, 2015, 85.
37. Kong, H.R., Geng, S., Yang, J., Zeng, F.Y., L.M. Center, N. Hospital, S.M. University, Effects of downregulated ATP citrate lyase on the growth and apoptosis of prostate cancer cells. J. Med. Postgrad. 30 (2017), 26–30.
38. Khwairakpam, A.D., Shyamananda, M., Sailo, B.L., Rathnakaram, S.R., Padmavathi, G., Kotoky, J., Kunnumakkara, A.B., ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr. Drug Targets, 16, 2015, 156.
39. Lucenay, K.S., Doostan, I., Karakas, C., Bui, T., Ding, Z., Mills, G.B., Hunt, K.K., Keyomarsi, K., Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Res., 76, 2016.
40. Ding, Q., Zhou, F., Expression of ATP-citrate lyase in hepatocellular carcinoma and its clinical significance. Med. J. Wuhan Univ. 36 (2015), 39–44.
41. Qian, X., Hu, J., Zhao, J., Hong, C., ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma. Int. J. Clin. Exp. Med. 8 (2015), 7855–7860.
42. Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., ATP citrate lyase: Activation and therapeutic implications in non–small cell lung cancer. Cancer Res. 68 (2008), 8547–8554.
43. Bauer, D.E., Hatzivassiliou, G., Zhao, F., Andreadis, C., Thompson, C.B., ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24 (2005), 6314–6322.
44. Sato, R., Okamoto, A., Inoue, J., Miyamoto, W., Sakai, Y., Emoto, N., Shimano, H., Maeda, M., Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins. J. Biol. Chem. 275 (2000), 12497–12502.
45. Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., Okumura, S., Nakagawa, K., Ishikawa, Y., ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 68 (2008), 8547–8554.
46. Lord, K.A., Wang, X.-M., Simmons, S.J., Bruckner, R.C., Loscig, J., O'Connor, B., Bentley, R., Smallwood, A., Chadwick, C.C., Stevis, P.E., Variant cDNA sequences of human ATP: citrate lyase: cloning, expression, and purification from baculovirus-infected insect cells. Protein Expr. Purif. 9 (1997), 133–141.
47. Wagner, P.D., Vu, N.D., Phosphorylation of ATP-citrate lyase by nucleoside diphosphate kinase. J. Biol. Chem., 270, 1995, 21758.
48. Pierce, M.W., Palmer, J.L., Keutmann, H.T., Avruch, J., ATP-citrate lyase. Structure of a tryptic peptide containing the phosphorylation site directed by glucagon and the cAMP-dependent protein kinase. J. Biol. Chem. 256 (1981), 8867–8870.
49. Fukuda, H., Katsurada, A., Iritani, N., Effects of nutrients and hormones on gene expression of ATP citrate-lyase in rat liver. Eur. J. Biochem. 209 (1992), 217–222.
50. Hatzivassiliou, G., Zhao, F., Bauer, D.E., Andreadis, C., Shaw, A.N., Dhanak, D., Hingorani, S.R., Tuveson, D.A., Thompson, C.B., ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8, 2005, 311.
51. Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Taguchi, R., Soga, T., Seimiya, H., Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact. Am. J. Pathol. 182 (2013), 1800–1810.
52. Infantino, V., Iacobazzi, V., Palmieri, F., Menga, A., ATP-citrate lyase is essential for macrophage inflammatory response. Biochem. Biophys. Res. Commun. 440 (2013), 105–111.
53. Zimmer, A.D., Walbrecq, G., Kozar, I., Behrmann, I., Haan, C., Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells. Hypoxia 4 (2016), 135–145.
54. Jha, M.K., Suk, K., Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas. Brain Tumor Res. Treat. 1 (2013), 57–63.
55. Zhang, S.L., Hu, X., Zhang, W., Yao, H., Tam, K.Y., Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents. Drug Discov. Today 20 (2015), 1112–1119.
56. Patel, M.S., Nemeria, N.S., Furey, W., Jordan, F., The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem. 289 (2014), 16615–16623.
57. Yu, X., Hiromasa, Y., Tsen, H., Stoops, J.K., Roche, T.E., Zhou, Z.H., Structures of the human pyruvate dehydrogenase complex cores: a highly conserved catalytic center with flexible N-terminal domains. Structure 16 (2008), 104–114.
58. Sugden, M.C., Holness, M.J., The pyruvate carboxylase-pyruvate dehydrogenase axis in islet pyruvate metabolism: going round in circles?. Islets 3 (2011), 302–319.
59. Patel, M.S., Nemeria, N.S., Furey, W., Jordan, F., The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem., 289, 2014, 16615.
60. Patel, M.S., Korotchkina, L.G., Regulation of the pyruvate dehydrogenase complex. Biochem. Soc. Trans., 34, 2006, 217.
61. Huang, B., Gudi, R., Wu, P., Harris, R.A., Hamilton, J., Popov, K.M., Isoenzymes of pyruvate dehydrogenase phosphatase. J. Biol. Chem. 273 (1998), 17680–17688.
62. Sugden, M.C., Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Arch. Physiol. Biochem., 3, 2006.
63. Sugden, M.C., Holness, M.J., Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am. J. Physiol. Endocrinol. Metab. 284 (2003), E855–862.
64. Kolobova, E., Tuganova, A., Boulatnikov, I., Popov, K.M., Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem. J., 358, 2001, 69.
65. Korotchkina, L.G., Patel, M.S., Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites. J. Biol. Chem., 276, 2001, 5731.
66. Korotchkina, L.G., Patel, M.S., Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J. Biol. Chem. 276 (2001), 37223–37229.
67. Holness, M.J., Sugden, M.C., Pyruvate dehydrogenase activities during the fed-to-starved transition and on re-feeding after acute or prolonged starvation. Biochem. J., 258, 1989, 529.
68. Sugden, M.C., Holness, M.J., Effects of re-feeding after prolonged starvation on pyruvate dehydrogenase activities in heart, diaphragm and selected skeletal muscles of the rat. Biochem. J. 262 (1989), 669–672.
69. Sugden, P.H., Simister, N.E., Role of multisite phosphorylation in the regulation of ox kidney pyruvate dehydrogenase complex. FEBS Lett. 111 (1980), 299–302.
70. Sutendra, G., Kinnaird, A., Dromparis, P., Paulin, R., Stenson, T.H., Haromy, A., Hashimoto, K., Zhang, N., Flaim, E., Michelakis, E.D., A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 158 (2014), 84–97.
71. Kim, J., Tchernyshyov, I., Semenza, G.L., Dang, C.V., HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 3, 2006, 177.
72. Guo, J., Hezaveh, S., Tatur, J., Zeng, A.P., Jandt, U., Reengineering of human pyruvate dehydrogenase complex: from disintegration to highly active agglomerates. Biochem. J. 474 (2016), 865–875.
73. Guevara, E.L., Yang, L., Birkaya, B., Zhou, J., Nemeria, N.S., Patel, M.S., Jordan, F., Global view of cognate kinase activation by the human pyruvate dehydrogenase complex. Sci. Rep., 7, 2017, 42760.
74. Tuganova, A., Popov, K.M., Role of protein-protein interactions in the regulation of pyruvate dehydrogenase kinase activity. Biochem. J. 387 (2005), 147–153.
75. Wang, J., Kumaran, S., Zhou, J., Nemeria, N., Tao, H., Kakalis, L., Park, Y.H., Birkaya, B., Patel, M.S., Jordan, F., Elucidation of the interaction loci of the human pyruvate dehydrogenase complex E2·E3BP core with pyruvate dehydrogenase kinase 1 and kinase 2 by H/D exchange mass spectrometry and nuclear magnetic resonance. Biochemistry 54 (2015), 69–82.
76. de Boer, V.C., Houten, S.M., A mitochondrial expatriate: nuclear pyruvate dehydrogenase. Cell 158 (2014), 9–10.
77. Way, L., Faktor, J., Dvorakova, P., Nicholson, J., Vojtesek, B., Graham, D., Ball, K.L., Hupp, T., Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein-protein interactions by the MDM2 ligand nutlin-3. Proteomics 16 (2016), 2327–2344.
78. Ng, F., Tang, B.L., Pyruvate dehydrogenase complex (PDC) export from the mitochondrial matrix. Mol. Membr. Biol., 31, 2014, 207.
79. Cai, L., Sutter, B., Li, B., Tu, B., Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol. Cell, 42, 2011, 426.
80. Sutendra, G., Kinnaird, A., Dromparis, P., Paulin, R., Stenson, T.H., Haromy, A., Hashimoto, K., Zhang, N., Flaim, E., Michelakis, E.D., A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell, 158, 2014, 84.
81. Boukouris, A.E., Zervopoulos, S.D., Michelakis, E.D., Metabolic enzymes moonlighting in the nucleus: metabolic regulation of gene transcription. Trends Biochem. Sci., 41, 2016, 712.
82. Cai, L., Sutter, B.M., Li, B., Tu, B.P., Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol. Cell 42 (2011), 426–437.
83. Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Yung, W.K.A., Lu, Z., PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150 (2012), 685–696.
84. Semenza, G.L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 29, 2010, 625.
85. Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R.N., Pandey, A., Semenza, G.L., Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145 (2011), 732–744.
86. Byron, O., Lindsay, J.G., The pyruvate dehydrogenase complex and related assemblies in health and disease. Subcell. Biochem., 83, 2017, 523.
87. Jeoung, N.H., Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers. Diabetes Metab. J. 39 (2015), 188–197.
88. Stacpoole, P.W., The pyruvate dehydrogenase complex as a therapeutic target for age-related diseases. Aging Cell 11 (2012), 371–377.
89. Sun, W., Liu, Q., Leng, J., Zheng, Y., Li, J., The role of pyruvate dehydrogenase complex in cardiovascular diseases. Life Sci. 121 (2015), 97–103.
90. Hitosugi, T., Fan, J., Chung, T.-W., Lythgoe, K., Wang, X., Xie, J., Ge, Q., Gu, T.-L., Polakiewicz, R.D., Roesel, J.L., Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol. Cell 44 (2011), 864–877.
91. Saunier, E., Benelli, C., Bortoli, S., The pyruvate dehydrogenase complex in cancer: an old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int. J. Cancer, 138, 2016, 809.
92. Vary, T.C., Increased pyruvate dehydrogenase kinase activity in response to sepsis. Am. J. Physiol. 260 (1991), 669–674.
93. Park, H., Jeoung, N.H., Inflammation increases pyruvate dehydrogenase kinase 4 (PDK4) expression via the Jun N-terminal kinase (JNK) pathway in C2C12 cells. Biochem. Biophys. Res. Commun. 469 (2016), 1049–1054.
94. (!!! INVALID CITATION !!! 88).
95. Quigley, E.M., Primary biliary cirrhosis and the microbiome. Semin. Liver Dis., 36, 2016, 349.
96. Lleo, A., Invernizzi, P., Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. Dig. Liver Dis. 45 (2013), 630–636.
97. Kita, H., Matsumura, S., He, X.S., Ansari, A.A., Lian, Z.X., Van, d.W.J., Coppel, R.L., Kaplan, M.M., Gershwin, M.E., Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J. Clin. Investig. 109 (2002), 1231–1240.
98. Huang, Y., Zheng, J., Cytokines and Chemokines. 2017, Springer International Publishing, Place Published.
99. Li, J., Ge, M., Lu, S., Shi, J., Li, X., Min, W., Huang, J., Shao, Y., Huang, Z., Jing, Z., Pro-inflammatory effects of the Th1 chemokine CXCL10 in acquired aplastic anaemia. Cytokine 94 (2017), 45–51.
100. Schutte, K.M., Fisher, D.J., Burdick, M.D., Mehrad, B., Mathers, A.J., Mann, B.J., Nakamoto, R.K., Hughes, M.A., Escherichia coli pyruvate dehydrogenase complex is an important component of CXCL10-mediated antimicrobial activity. Infect. Immun., 84, 2015.
101. N.T., The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem., 29, 1986.
102. Noguchi, T., Yamada, K., Inoue, H., Matsuda, T., Tanaka, T., The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 262 (1987), 14366–14371.
103. David, C.J., Chen, M., Assanah, M., Canoll, P., Manley, J.L., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463 (2010), 364–368.
104. Keller, K., Doctor, Z., Dwyer, Z., Lee, Y.S., SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol. Cell 53 (2014), 700–709.
105. Ye, J., Mancuso, A., Tong, X., Ward, P.S., Fan, J., Rabinowitz, J.D., Thompson, C.B., Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl. Acad. Sci. U. S. A., 109, 2012, 6904.
106. Chaneton, B., Hillmann, P., Zheng, L., Martin, A.C., Maddocks, O.D., Chokkathukalam, A., Coyle, J.E., Jankevics, A., Holding, F.P., Vousden, K.H., Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491 (2012), 458–462.
107. Ashizawa, K., Mcphie, P., Lin, K.H., Cheng, S.Y., An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate. Biochemistry 30 (1991), 7105–7111.
108. Mazurek, S., Boschek, C.B., Hugo, F., Eigenbrodt, E., Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol., 2005, 300–308.
109. Lv, L., Xu, Y.P., Zhao, D., Li, F.L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T.T., Guan, K.L., Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 52 (2013), 340–352.
110. Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., Cantley, L.C., The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008), 230–233.
111. Israelsen, W.J., Dayton, T.L., Davidson, S.M., Fiske, B.P., Hosios, A.M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J.W., PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell, 155, 2013, 397.
112. WARBURG, O., On respiratory impairment in cancer cells. Science (New York, N.Y.) 124 (1956), 269–270.
113. Wong, N., Ojo, D., Yan, J., Tang, D., PKM2 contributes to cancer metabolism. Cancer Lett. 356 (2015), 184–191.
114. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
115. Wong, N., Melo, J.D., Tang, D., PKM2, a central point of regulation in cancer metabolism. Int. J. Cell Biol., 2013, 2013, 242513.
116. Gao, X., Wang, H., Yang, J.J., Liu, X., Liu, Z.R., Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell, 45, 2012, 598.
117. Gumińska, M., Stachurska, M.B., Ignacak, J., Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour, Morris hepatoma 7777 and normal mouse and rat livers. Biochim. Biophys. Acta 966 (1988), 207–213.
118. Hoshino, A., Hirst, J.A., Fujii, H., Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J. Biol. Chem. 282 (2007), 17706–17711.
119. Steták, A., Veress, R., Ovádi, J., Csermely, P., Kéri, G., Ullrich, A., Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res., 67, 2007, 1602.
120. Spoden, G.A., Morandell, D., Ehehalt, D., Fiedler, M., Jansendürr, P., Hermann, M., Zwerschke, W., The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell. Biochem. 107 (2009), 293–302.
121. Yang, W., Zheng, Y., Yan, X., Ji, H., Chen, X., Fang, G., Lyssiotis, C.A., Kenneth, A., Cantley, L.C., Lu, Z., ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14 (2012), 1295–1304.
122. Yang, W., Lu, Z., Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12 (2013), 3154–3158.
123. Li, N., Feng, L., Liu, H., Wang, J., Kasembeli, M., Tran, M.K., Tweardy, D., Lin, S.H., Chen, J., PARP inhibition suppresses growth of EGFR-mutant cancers by targeting nuclear PKM2. Cell Rep. 15 (2016), 843–856.
124. Wang, H.-J., Hsieh, Y.-J., Cheng, W.-C., Lin, C.-P., Lin, Y.-s., Yang, S.-F., Chen, C.-C., Izumiya, Y., Yu, J.-S., Kung, H.-J., JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α–mediated glucose metabolism. Proc. Natl. Acad. Sci. 111 (2014), 279–284.
125. Anastasiou, D., Yu, Y., Israelsen, W.J., Jiang, J.K., Boxer, M.B., Hong, B.S., Tempel, W., Dimov, S., Shen, M., Jha, A., Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol., 8, 2012, 839.
126. Y.Z., H.L., Q.P., J.A., W.L., Y.T., T.S., Z.W., R.C., PKM2 Thr454 phosphorylation increases its nuclear translocation and promotes xenograft tumor growth in A549 human lung cancer cells. Biochem. Biophys. Res. Commun., 473, 2016, 953.
127. Ignacak, J., Stachurska, M.B., The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 134 (2003), 425–433.
128. Jiang, Y., Li, X., Yang, W., Hawke, D., Zheng, Y., Yan, X., Aldape, K., Wei, C., Fang, G., Yan, C., PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell, 53, 2014, 75.
129. Luo, W., Semenza, G.L., Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2 (2011), 551–556.
130. Lee, J., Kim, H.K., Han, Y.M., Kim, J., Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol., 40, 2008, 1043.
131. Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., Lu, Z., Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480 (2011), 118–122.
132. Chen, L., Shi, Y., Liu, S., Cao, Y., Wang, X., Tao, Y., PKM2: the thread linking energy metabolism reprogramming with epigenetics in cancer. Int. J. Mol. Sci. 15 (2014), 11435–11445.
133. Konno, M., Ishii, H., Koseki, J., Tanuma, N., Nishida, N., Kawamoto, K., Nishimura, T., Nakata, A., Matsui, H., Noguchi, K., Pyruvate kinase M2, but not M1, allele maintains immature metabolic states of murine embryonic stem cells. Regen. Ther. 1 (2015), 63–71.
134. Zhang, X., He, C., He, C., Chen, B., Liu, Y., Kong, M., Wang, C., Lin, L., Dong, Y., Sheng, H., Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol. Res. Pract. 209 (2013), 510–515.
135. Jiang, Y., Yan, B., Lai, W., Shi, Y., Xiao, D., Jia, J., Liu, S., Li, H., Lu, J., Li, Z., Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8. Oncogene 34 (2015), 6079–6091.
136. Guoqing, G.U., Fei, S., Expression and significance of PKM2 and HIF-1α in esophageal carcinoma. J. Baotou Med. Coll. 32 (2016), 5–6.
137. Guo, C.Y., Yan, C., Luo, L., Goto, S., Urata, Y., Xu, J.J., Wen, X.M., Kuang, Y.K., Tou, F.F., Li, T.S., Enhanced expression of PKM2 associates with the biological properties of cancer stem cells from A549 human lung cancer cells. Oncol. Rep. 37 (2017), 2161–2166.
138. Yang, C., Value of plasma tumor M2 pyruvate kinase in diagnosis and monitoring of rectal cancer. Int. J. Lab. Med. 37 (2016), 1654–1656.
139. Wu, J., Hu, L., Chen, M., Cao, W., Chen, H., He, T., Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies. Oncotargets Ther., 9, 2016, 4277.
140. Guo, M., Zhao, X., Yuan, X., Jiang, J., Li, P., MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in cervical cancer. Oncotarget, 8, 2017, 28226.
141. Xing, W., Zhang, F., Wu, X.R., Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin. Sci. Rep., 7, 2017, 45983.
142. Mohammad, G.H., Damink, S.W.M.O., Malago, M., Dhar, D.K., Pereira, S.P., Pyruvate kinase M2 and lactate dehydrogenase A are overexpressed in pancreatic cancer and correlate with poor outcome. PLoS One, 11, 2016.
143. Chiavarina, B., Whitakermenezes, D., Martinezoutschoorn, U.E., Witkiewicz, A.K., Birbe, R.C., Howell, A., Pestell, R.G., Smith, J., Daniel, R., Sotgia, F., Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther. 12 (2011), 1101–1113.
144. Hsu, M.C., Hung, W.C., Yamaguchi, H., Lim, S.O., Liao, H.W., Tsai, C.H., Hung, M.C., Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. Am. J. Cancer Res. 6 (2016), 628–638.
145. L.Z., Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin. J. Cancer, 31, 2012, 5.
146. Yang, W., Xia, Y., Cao, Y., Zheng, Y., Bu, W., Zhang, L., You, M.J., Koh, M.Y., Cote, G., Aldape, K., EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell, 48, 2012, 771.
147. Dong, G., Mao, Q., Xia, W., Xu, Y., Wang, J., Xu, L., Jiang, F., PKM2 and cancer: the function of PKM2 beyond glycolysis. Oncol. Lett., 11, 2016, 1980.
148. Miao, Y., Feng, Y.J., Research advances in expression regulation and clinical application of pyruvate kinase M2 in tumor metabolism and growth. J. Shanghai Jiaotong Univ. 36 (2016), 1079–1083.
149. Ninel, A., Alexander, B., Konrad, S., Arefeh, R., Kristina, D., Felicitas, G., Thomas, S., Thomas, S., PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation. Mol. Cancer 15 (2016), 1–15.
150. Lee, K.M., Nam, K., Oh, S., Lim, J., Lee, T., Shin, I., ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2. Cell. Signal. 27 (2015), 228–235.
151. Cheng, K., Hao, M., Metformin inhibits TGF-β1-induced epithelial-to-mesenchymal transition via PKM2 Relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells. Int. J. Mol. Sci., 17, 2016, 2000.
152. Zhao, S., Venkatasubbarao, K., Lazor, J.W., Sperry, J., Jin, C., Cao, L., Freeman, J.W., Inhibition of STAT3Tyr705 phosphorylation by Smad4 suppresses transforming growth factor β–mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 68 (2008), 4221–4228.
153. Bhardwaj, A., Das, S., SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 899–909.
154. Tsuyoshi, S., Nazarewicz, R.R., Wallis, B.B., Yanes, R.E., Ryu, W., Marc, H., Tian, L., Harrison, D.G., Giacomini, J.C., Assimes, T.L., The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J. Exp. Med., 213, 2016, 337.
155. Deng, J., Lü, S., Liu, H., Bo, L., Jiang, C., Xu, Q., Feng, J., Xian, W., Homocysteine activates B cells via regulating PKM2-dependent metabolic reprogramming. J. Immunol. 198 (2016), 170–183.
156. Xie, M., Yu, Y., Kang, R., Zhu, S., Yang, L., Zeng, L., Sun, X., Yang, M., Billiar, T.R., Wang, H., PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat. Commun., 7, 2016, 13280.
157. Miyake, Y., Ishii, K., Honda, A., Influenza virus infection induces host pyruvate kinase M which interacts with viral RNA-dependent RNA polymerase. Front. Microbiol., 8, 2017, 162.
158. Shinohara, H., Taniguchi, K., Kumazaki, M., Yamada, N., Ito, Y., Otsuki, Y., Uno, B., Hayakawa, F., Minami, Y., Naoe, T., Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoforms expression profile mediated by bcr-abl in chronic myeloid leukemia. Cancer Lett. 360 (2015), 28–38.
159. Liu, J., Wu, N., Ma, L., Liu, M., Liu, G., Zhang, Y., Lin, X., Oleanolic acid suppresses aerobic glycolysis in cancer cells by switching pyruvate kinase type M isoforms. PLoS One, 9, 2014, e91606.
160. Chen, Z., Wang, Z., Guo, W., Zhang, Z., Zhao, F., Zhao, Y., Jia, D., Ding, J., Wang, H., Yao, M., TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma. Oncogene, 34, 2015, 3946.
161. Zhang, J., Feng, G., Bao, G., Xu, G., Sun, Y., Li, W., Wang, L., Chen, J., Jin, H., Cui, Z., Nuclear translocation of PKM2 modulates astrocyte proliferation via p27 and β-catenin pathway after spinal cord injury. Cell Cycle 14 (2015), 2609–2618.
162. Xu, H., Luo, J., Ma, G., Zhang, X., Yao, D., Li, M., Loor, J.J., Acyl-CoA synthetase short-chain family member 2 (ACSS2) is regulated by SREBP-1 and plays a role in fatty acid synthesis in caprine mammary epithelial cells. J. Cell. Physiol., 2017, 10.1002/jcp.25954.
163. Gizak, A., Rakus, D., Dzugaj, A., Nuclear localization of fructose 1,6-bisphosphatase in smooth muscle cells. J. Mol. Histol. 36 (2005), 243–248.
164. Fotie, J., Inosine 5′-monophosphate dehydrogenase (IMPDH) as a potential target for the development of a new generation of antiprotozoan agents. Mini-Rev. Med. Chem., 16, 2016.
165. Holzer, K., Drucker, E., Roessler, S., Dauch, D., Heinzmann, F., Waldburger, N., Eiteneuer, E.M., Herpel, E., Breuhahn, K., Zender, L., Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. 2016.
166. Joo, H.Y., Woo, S.R., Shen, Y.N., Yun, M.Y., Shin, H.J., Park, E.R., Kim, S.H., Park, J.E., Ju, Y.J., Hong, S.H., SIRT1 interacts with and protects glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from nuclear translocation: implications for cell survival after irradiation. Biochem. Biophys. Res. Commun. 424 (2012), 681–686.
167. Igarashi, K., Kera, Y., Katoh, Y., Nuclear function of methionine adenosyltransferase II in oxidative stress response. Annu. Meet. Jpn. Soc. Toxicol., 2012, S1–3.
168. Song, T., Yang, L., Kabra, N., Chen, L., Koomen, J., Haura, E.B., Chen, J., The NAD + synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription. J. Biol. Chem., 288, 2013, 20908.
169. Yun, J., Johnson, J.L., Hanigan, C.L., Locasale, J.W., Interactions between epigenetics and metabolism in cancers. Front. Oncol., 2, 2012, 163.
170. Etchegaray, J.P., Mostoslavsky, R., Interplay between metabolism and epigenetics: a nuclear adaptation to environmental changes. Mol. Cell, 62, 2016, 695.